Изучение затрат на фармакотерапию пациентов с внебольничной пневмонией в педиатрической практике с использованием математико-статистических методов анализастатья
Дата последнего поиска статьи во внешних источниках: 7 июля 2020 г.
Аннотация:The aim of the study is to determine the limits of using the mathematical-statistical analysis for the evaluation of pharmacotherapy costs in
pediatric inpatients diagnosed with community-acquired pneumonia. Materials and methods. The report is based on the assessment of 547
medical records of patients with community-acquired pneumonia, who underwent the treatment in four pediatric hospitals in St. Petersburg.
The data array was created from a number of factors that characterize the patients’ profile (gender, duration of hospital stay, cost of therapy,
number of prescribed drugs, number of affected lung segments, pathogen location, leukocyte count, and ESR). Results. Correlation analysis
allowed us to identify factors contributing to the cost of pharmacotherapy (at a significance of p=0.05); those were: the duration of hospital
stay (r=0.34), the number of prescribed drugs (r=0.26), and the number of affected lung segments (r=0.21). Dispersion analysis of qualitative
factors (gender, location of pneumonic infiltrate) showed no significant impact of these factors on the costs or the number of prescribed drugs
in the total data set. From the regression analysis, we obtained formulas for the dependence of the resulting parameters (cost of
pharmacotherapy, number of prescribed drugs) on a set of independent variables. Conclusion. The treatment cost optimization in pediatric
patients with community-acquired pneumonia should include the use of antibacterial drugs with proven efficacy and safety, as well as a
reduction in non-necessary supporting therapy, e.g., medications aimed to correct morphological and functional changes in the respiratory
system.